- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Hyperprolactinemia.
Displaying page 1 of 1.
| EudraCT Number: 2021-005579-38 | Sponsor Protocol Number: 1 | Start Date*: 2022-01-31 | |||||||||||
| Sponsor Name:Aarhus University Hospital, Department of Endocrinology | |||||||||||||
| Full Title: Cabergoline as a Preventive Treatment for Chronic Migraine: an Investigator-Initiated, Randomized Clinical Trial | |||||||||||||
| Medical condition: Migraine | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-021403-24 | Sponsor Protocol Number: 001 | Start Date*: 2010-11-10 | |||||||||||
| Sponsor Name:North Lincolnshire and Goole NHS Foundation Trust | |||||||||||||
| Full Title: A Prospective Pilot Study to Investigate the Effectiveness of Quinagolide in the Improvement of Psychological Symptoms Associated with Hyperprolactinaemia. | |||||||||||||
| Medical condition: Hyperprolactinaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-011228-73 | Sponsor Protocol Number: OCTUMI-03 | Start Date*: 2010-02-09 | |||||||||||
| Sponsor Name:University of Oxford [...] | |||||||||||||
| Full Title: A pilot study of Aripiprazole treatment for antipsychotic induced hyperprolactinaemia in young patients with severe mental illness and learning disabilities. | |||||||||||||
| Medical condition: Antipsychotic induced hyperprolactinaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2023-000082-13 | Sponsor Protocol Number: GR-2021-12374243 | Start Date*: 2023-04-14 | |||||||||||
| Sponsor Name:AZIENDA USL DI BOLOGNA | |||||||||||||
| Full Title: Surgical versus Medical Treatment in Microprolactinomas (SUMET PRO) | |||||||||||||
| Medical condition: Microprolactinomas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-001181-41 | Sponsor Protocol Number: CN138-125 | Start Date*: 2005-01-10 |
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||
| Full Title: A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices | ||
| Medical condition: Schizophrenia or schizoaffective disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SK (Completed) CZ (Completed) HU (Completed) LT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002108-11 | Sponsor Protocol Number: SEP380-303 | Start Date*: 2022-02-10 | |||||||||||
| Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
| Full Title: A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ... | |||||||||||||
| Medical condition: Major Depressive Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012003-26 | Sponsor Protocol Number: RIS-NAP-4022 | Start Date*: 2010-04-13 | |||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International, NV | |||||||||||||||||||||||
| Full Title: Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs | |||||||||||||||||||||||
| Medical condition: Long-term safety data in children and adolescents will be collected from a population of patients with a diagnosis of schizophrenia, bipolar mania, autistic disorder or conduct and other disruptive... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GR (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2012-004546-15 | Sponsor Protocol Number: 12-PP-12 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:CHU de Nice | |||||||||||||
| Full Title: Assessment of incidence of adverse events in a naive pediatric population treated with an antipsychotic drug over 12 months follow-up | |||||||||||||
| Medical condition: severe behavioral disorders in mental retardation, autistic syndromes schizophrenia psychosis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.